Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?
  • Published Date:
    Jun 30 2009
  • Source:
    PLoS Med. 6(6).
Filetype[PDF-72.35 KB]


No Related Documents.
You May Also Like:
  1. Vaccines and Antiviral Drugs in Pandemic Preparedness
    Personal Author:
    Monto, Arnold S.
    Published Date:
    Jan 2006
    Source:
    Emerg Infect Dis. 12(1):55-60.
    Description:
    While measures such as closing schools and social distancing may slow the effects of pandemic influenza, only vaccines and antiviral drugs are clearly efficacious in preventing infection or treating illness. Unless the pandemic strain closely resembl...
    File Type:
    Filetype[PDF - 76.80 KB]
  2. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1
    Personal Author:
    Mishin, Vasiliy P.; Patel, Mira C.; Chesnokov, Anton; De La Cruz, Juan; Nguyen, Ha T.; Lollis, Lori; Hodges, Erin; Jang, Yunho; Barnes, John; Uyeki, Timothy; Davis, Charles T.; Wentworth, David E.; Gubareva, Larisa V.;
    Published Date:
    October 17 2019
    Source:
    Emerg Infect Dis. 25(10):1969-1972
    Description:
    Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses o...
    File Type:
    Filetype[PDF - 700.01 KB]
  3. H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
    Personal Author:
    Renaud, Christian; Boudreault, Alexandre A.; Kuypers, Jane; Lofy, Kathryn H.; Corey, Lawrence; Boeckh, Michael J.; Englund, Janet A.;
    Published Date:
    Apr 2011
    Source:
    Emerg Infect Dis. 17(4):653-660.
    Description:
    Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275...
    File Type:
    Filetype[PDF - 420.34 KB]
  4. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins
    Personal Author:
    Marjuki, Henju; Mishin, Vasiliy P.; Chai, Ning; Tan, Man-Wah; Newton, Elizabeth M.; Tegeris, John; Erlandson, Karl; Willis, Melissa; Jones, Joyce; Davis, Todd; Stevens, James; Gubareva, Larisa V.;
    Published Date:
    Nov 14 2016
    Source:
    J Virol. 2016; 90(23):10446-10458.
    Description:
    The pandemic threat posed by emerging zoonotic influenza A viruses necessitates development of antiviral agents effective against various antigenic subtypes. Human monoclonal antibody (hMAb) targeting the hemagglutinin (HA) stalk offers a promising a...
    File Type:
    Filetype[PDF - 3.28 MB]
  5. 5'PPP-RNA induced RIG-I activation inhibits drug-resistant avian H5N1 as well as 1918 and 2009 pandemic influenza virus replication
    Personal Author:
    Ranjan, Priya; Jayashankar, Lakshmi; Deyde, Varough; Zeng, Hui; Davis, William G; Pearce, Melissa B.; Bowzard, John B.; Hoelscher, Mary A; Jeisy-Scott, Victoria; Wiens, Mayim E.; Gangappa, Shivaprakash; Gubareva, Larisa; García-Sastre, Adolfo; Katz, Jacqueline M..; Tumpey, Terrence M; Fujita, Takashi; Sambhara, Suryaprakash;
    Published Date:
    May 21 2010
    Source:
    Virol J. 2010; 7:102.
    Description:
    BackgroundEmergence of drug-resistant strains of influenza viruses, including avian H5N1 with pandemic potential, 1918 and 2009 A/H1N1 pandemic viruses to currently used antiviral agents, neuraminidase inhibitors and M2 Ion channel blockers, undersco...
    File Type:
    Filetype[PDF - 1.03 MB]